A Metabolic Imaging Severity Rating Scale for the Assessment of Cognitive Impairment

Clinical Nuclear Medicine

Volumn 28, Issue 7, 2003, Pages 565-570

  Newberg, Andrew ^a   Cotter, Adolfo ^a   Udeshi, Michelle ^a   Alavi, Abass ^a   Clark, Christopher ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebral Metabolism; Cognitive Impairment; Positron Emission Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CEREBELLUM; COGNITIVE DEFECT; DEMENTIA; DEMENTIA SEVERITY RATING SCORE; DISEASE SEVERITY; FRONTAL LOBE; FRONTAL LOBE DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; METABOLIC IMAGING; METABOLIC IMAGING SEVERITY RATING SCALE; MINI MENTAL STATUS EXAMINATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION FIELD; RATING SCALE; REGION OF INTEREST; SCORING SYSTEM; SENSORIMOTOR CORTEX; THALAMUS; VALIDATION PROCESS; VISUAL CORTEX; BRAIN; BRAIN MAPPING; CLASSIFICATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HOSPITALIZATION; METABOLISM; METHODOLOGY; PSYCHOLOGIC TEST; SCINTISCANNING; STATISTICS; VALIDATION STUDY;

BRAIN; BRAIN MAPPING; COGNITION DISORDERS; FLUORODEOXYGLUCOSE F18; HUMANS; PSYCHOLOGICAL TESTS; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141833935     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200307000-00006     Document Type: Article

References (21)

1. Johannsen P, Jakobsen J, Gjedde A: Statistical maps of cerebral blood flow deficits in Alzheimer's disease. Eur J Neurol 7:385, 2000.
2. Ishii K, Sasaki M, Matsui M, et al: A diagnostic method for suspected Alzheimer's disease using H(2)150 positron emission tomography perfusion Z score. Neuroradiology 42:787, 2000.
3. Yamaji S, Ishii K, Sasaki M, et al: Evaluation of standardized uptake value to assess cerebral glucose metabolism. Clin Nucl Med 25:11, 2000.
4. Jelic V, Nordberg A: Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord 14(Suppl 1):S109, 2000.
5. Pietrini P, Alexander GE, Furey ML, et al: The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Int J Psychophysiol 37:87, 2000.
6. Small GW, Ercoli LM, Silverman DH, et al: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97:6037, 2000.
7. Berent S, Giordani B, Foster N, et al: Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res 33:7, 1999.
8. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939, 1984.
9. Clark CM, Ewbank DC: Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 10:31, 1996.
10. Karp JS, Muehllehner G, Mankoff DA, et al: Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. J Nucl Med 31:617, 1990.
11. Chang LT: A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 25:638, 1978.
12. Kumar A, Newberg AB, Alavi A, et al: MRI volumetric measures in Alzheimer's disease: relationship to clinical and neuropsychological variables. Am J Geriatr Psychiatr 2:21, 1994.
13. Dickerson BC, Goncharova I, Sullivan MP, et al: MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 22:747, 2001.
14. Sencakova D, Graff-Radford NR, Willis FB, et al: Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans. Arch Neurol 58:1593, 2001.
15. De Santi S, de Leon MJ, Rusinek H, et al: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22:529, 2001.
16. Foster NL, Chase TN, Mansi L, et al: Cortical abnormalities in Alzheimer's disease. Ann Neurol 16:649, 1984.
17. Jagust WJ, Friedland RP, Budinger TF, et al: Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 38:909, 1988.
18. Newberg A, Alavi A, Souder E, et al: A comparison of FDG-PET and MRI data from patients with atypical dementias and Alzheimer's disease (AD) [Abstract]. J Nucl Med 33:965, 1992.
19. Hirono N, Mori E, Ishii K, et al: Regional hypometabolism related to language disturbance in Alzheimer's disease. Dement Geriatr Cogn Disord 9:68, 1998.
20. Cummings JL: Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging 21:845, 2000.
21. Shinosaki K, Nishikawa T, Takeda M: Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatr Clin Neurosci 54:611, 2000.